Biotech Values

[DewDiligence]

>Ambati said the main implications of his research are two fold:
1. for researchers to understand how siRNAs actually work
2. for clinical trials of siRNA to be approached with great caution.<

I would add a third implication: that investors ought to be particularly disciplined regarding the valuation of such companies as ALNY, RXII, and ROSG.

p.s. I’m impressed that you remembered the thread about Sirna-027.